Regulatory approval

Published by the Health Service Executive. Approved

As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

This is written in the approval document.

Reimbursement

CDS

Citation

Ibrutinib Therapy - Mantle Cell Lymphoma, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6953/297_Ibrutinib_MCL.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) t(11;14) Mantle Cell Lymphoma Ibrutinib
HSE (1) CCND1 Mantle Cell Lymphoma Ibrutinib